HIHiroshi Imamura

Hiroshi Imamura

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hiroshi Imamura has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A sonographic software program, Fluctuational Imaging, for diagnosis of hepatic hemangioma

    by Hiroshi Imamura, Jiro Hata

    Hepatic hemangioma is the most common benign solid lesion of the liver. Contrast-enhanced computed tomography or magnetic resonance imaging is recommended for definitive diagnosis of hepatic hemangioma. However, these modalities have drawbacks in terms of radiation exposure, invasiveness, and high cost for examination. “Fluttering sign” is one of the candidate findings considered specific for hepatic hemangioma that can be useful for diagnosis of hepatic hemangioma using grayscale US alone. However, the assessment is subjective and the findings are weak and likely to be overlooked in some cases. We developed a software program, Fluctuational Imaging, for objective detection and depiction of “fluttering sign”. Here, we evaluated the ability of Fluctuational Imaging software to depict “fluttering sign” in hepatic hemangioma. Presence or absence of “fluttering sign” was evaluated in the grayscale US videos and Fluctuational Imaging software analysis results of patients with hepatic hemangioma. The Cohen’s kappa test showed very good agreement (0.95). Fluctuational Imaging software can detect and depict the phenomenon of “fluttering sign” well and may be a useful tool for diagnosis of hepatic hemangioma.


  • Open Access

    The Use of Transabdominal Ultrasound in Inflammatory Bowel Disease

    by Jiro Hata, Hiroshi Imamura

    Hata J, et al. Korean J Radiol. 2022 Mar;23(3):308-321. https://doi.org/10.3348/kjr.2021.0692


  • Contrast-enhanced ultrasonographic findings of non-occlusive mesenteric ischemia: a case series

    by Hiroshi Imamura, Jiro Hata, Tamako Takata

    Purpose Diagnosis of non-occlusive mesenteric ischemia (NOMI) is difficult, with diagnostic imaging being mainly performed using angiography or contrast-enhanced computed tomography. Contrast-enhanced ultrasonography (CEUS) offers an alternative diagnostic method, although diagnosis of NOMI using CEUS is not common. In this report, we review CEUS findings in a series of patients with NOMI. Methods The records of patients diagnosed with NOMI who underwent a surgical procedure in our institution between January 2015 and February 2020 were retrospectively assessed. Grayscale ultrasonography and CEUS findings were evaluated. Results Ten patients (mean age 65 ± 25 years, 7 men) were studied. Grayscale ultrasonography revealed bowel dilatation, the presence of intestinal pneumatosis, portal venous gas, bowel wall thickening, and no or decreased peristalsis. A CEUS finding of note was a partial lack of enhancement of the bowel wall. Conclusion In a small case series of 10 patients with surgically/histopathology confirmed NOMI, partial lack of ultrasound contrast-enhancement of the bowel wall was observed.


  • Open Access

    Increased enhancement of the liver adjacent to the gallbladder seen with contrast ultrasound: comparison between acute cholecystitis and non-cholecystitis

    by Ryousuke Kawai, Jiro Hata, Noriaki Manabe, Hiroshi Imamura, Ai Iida, Nobuko Koyama, Hiroaki Kusunoki

    This study was performed to evaluate the ability of contrast-enhanced ultrasonography (CEUS) with time-intensity curve analysis to demonstrate an increased enhancement of the liver parenchyma adjacent to the inflamed gallbladder, as seen on contrast-enhanced computed tomography. The Ethics Committee of our institution approved the study protocol (Kawasaki Medical School, registration number 1277). From April to November 2013, 11 consecutive patients with acute cholecystitis and 16 patients without cholecystitis consented to CEUS (Sonazoid™) and were enrolled in this study. The gallbladder and liver were scanned by one gastroenterologist using harmonic imaging with a low mechanical index. The raw imaging data were stored. Another physician, blinded to all clinical information, constructed the time-intensity curve. The major axis of the region of interest (ROI) was set in segment 5 (pericholecystic area), and the control ROI in segment 8 at the same depth. The intensity ratio (IR) was defined as the peak intensity of segment 5 divided by the simultaneous value of segment 8. The characteristics of the patient with and without acute cholecystitis were compared. The correlation between the IR and the presence of acute cholecystitis was analyzed using binomial logistic regression analysis. A receiver operating characteristic (ROC) curve analysis was performed as well. The IR was significantly higher in the group with than without acute cholecystitis (p = 0.006). The IR correlated significantly with the presence of acute gallbladder inflammation (p = 0.043). The area under the ROC curve was estimated as 0.852 (95 % confidence interval, 0.709–0.995). A cut-off value of 2.72 had a sensitivity of 81.8 % and a specificity of 81.3 %. The IR obtained by CEUS with time-intensity curve analysis generally demonstrated increased enhancement of the liver parenchyma adjacent to the inflamed gallbladder.


  • Contrast-enhanced ultrasonography with Sonazoid for diagnosis of gangrenous cholecystitis

    by Ryousuke Kawai, Jiro Hata, Noriaki Manabe, Hiroshi Imamura, Ai Iida, Rui Nakatou, Nobuko Koyama, Toshihiro Hirai, Yoshito Sadahira

    This prospective study investigated the ability of contrast-enhanced ultrasonography (CEUS) with Sonazoid to diagnose gangrenous cholecystitis and determined the inter-observer agreement. From September 2012 to August 2014, 27 patients with acute cholecystitis underwent preoperative CEUS (registration number 1277). After Sonazoid injection, harmonic imaging of the gallbladder wall was performed, and the findings were recorded using movie clips. The signal intensity was classified as absence (uncomplicated) or presence of perfusion defects (gangrenous). The physician performing CEUS recorded the findings immediately after the examination. Another physician (blinded to the clinical information) then reviewed the movie clips and recorded the findings. The final diagnosis was determined by histological examination in all 27 patients. The final diagnosis was gangrenous cholecystitis in 15 patients and uncomplicated cholecystitis in 12. On CEUS examination, perfusion defects were detected in 10 patients with gangrenous cholecystitis, giving a sensitivity of 66.7 %, specificity of 100 %, positive predictive value of 100 %, and negative predictive value of 70.6 %. On review of the movie clips, these values were 73.3, 100, 100, and 75.0 %, respectively. The inter-observer agreement between physicians was good (κ coefficient, 0.64). CEUS with Sonazoid is a useful and reproducible modality for diagnosing gangrenous cholecystitis.


  • Evaluating the effects of diclofenac sodium and etodolac on renal hemodynamics with contrast-enhanced ultrasonography: a pilot study

    by Hiroshi Imamura, Jiro Hata, Ai Iida, Noriaki Manabe, Ken Haruma

    Contrast-enhanced ultrasonography (CEUS) is a novel approach used for measuring organ perfusion changes. Studies using CEUS to assess the effects of non-steroidal anti-inflammatory drugs (NSAIDs) on renal blood flow (RBF) have not yet been conducted. We aimed to evaluate the effects of NSAIDs on the renal hemodynamics of healthy subjects with CEUS.


  • Randomized phase II trial of S-1 plus irinotecan versus S-1 plus paclitaxel as first-line treatment for advanced gastric cancer (OGSG0402): Final report.

    by T. Kishimoto, H. Imamura, F. Uedou, K. Fujitani, S. Iijima, H. Takiuchi, M. Imano, T. Shimokawa, Y. Kurokawa, H. Furukawa

    4015 Background: S-1-based regimens are commonly used for advanced gastric cancer (AGC) in Japan. Both S-1 plus irinotecan (SI) and S-1 plus paclitaxel (SP) have shown an overall response rate (ORR) of 48% in respective phase II trials. This randomized phase II trial evaluated these two S-1-based regimens in terms of ORR as first-line treatment for AGC in order to choose the optimal regimen for a phase III trial. Methods: Patients with previously untreated, locally advanced and/or metastatic measurable gastric adenocarcinoma, a performance status of < 2, and adequate organ function were randomly assigned to receive S-1 (80 mg/m2/day) for 21 consecutive days plus irinotecan (80 mg/m2) on days 1 and 15, repeated every 5 weeks for the SI arm, or the same dose of S-1 for 14 consecutive days plus paclitaxel (50 mg/m2) on days 1 and 8, repeated every 3 weeks for the SP arm. Both treatments were continued until disease progression or intolerable toxicity occurred. Study endpoints included ORR as primary, progres...